Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems?
On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This significant trade comes in the wake of Wood's previous remarks about the tech giant being "really expensive and very obvious".
星期一， 凱茜伍德-領先 方舟投資 通過出售價值近400萬美元的，採取了顯著的舉動 英偉達公司 納斯達克股票代碼：NVDA）股票。這筆重大交易是在伍德此前發表言論稱這家科技巨頭 “非常昂貴且非常明顯” 之後進行的。
The NVIDIA Trade
英偉達交易
Ark sold 8983 shares of the Jensen Huang-led company through the ARK Genomic Revolution ETF (BATS:ARKG). The transaction was valued at $4.02 million — based on the stock's closing price of $447.82 on Monday.
方舟出售了 8983 股股份 黃仁森-帶領公司度過難關 ARK 基因組革命 ETF （BATS: ARKG）。根據該股週一的收盤價447.82美元，該交易的價值爲402萬美元。
Ark Invest's decision to offload NVIDIA shares aligns with Cathie Wood's earlier sentiments. Wood has been vocal about her perspective, considering other less obvious but profitable avenues in the AI sector. The sale of NVIDIA, a company that recently crossed $1 trillion in market cap due to its 191% surge year to date, appears to underscore Ark's strategy to optimize its portfolio.
Ark Invest 拋售 NVIDIA 股票的決定與 凱茜伍德早些時候的觀點。伍德一直在大聲疾呼自己的觀點，考慮了人工智能領域其他不太明顯但有利可圖的途徑。NVIDIA的出售似乎凸顯了方舟優化其投資組合的戰略，該公司由於年初至今的市值激增了191％，其市值最近突破了1萬億美元。
See Also: Ark's NVIDIA Stake Dwindles Further
另見：Ark 的 NVIDIA 股份進一步減少
Other Key Trades:
其他關鍵交易：
- Ark Invest purchased 92,853 shares of SomaLogic Inc (NASDAQ:SLGC), a notable player in the biotechnology sector through ARKG.
- The firm also acquired 45,1942 shares of Recursion Pharmaceuticals (NASDAQ:RXRX), marking a significant addition to its holdings through ARKG.
- 22,220 shares of Beam Therapeutics Inc (NASDAQ:BEAM) were added to Ark's portfolio, emphasizing its focus on innovative biotech firms through.
- Ark Invest 購買了 92,853 股股票 SomaLogic 公司 納斯達克股票代碼：SLGC），通過ARKG成爲生物技術領域的知名參與者。
- 該公司還收購了45,1942股股份 遞歸製藥 納斯達克股票代碼：RXRX），這標誌着其通過ARKG的持股量大幅增加。
- 22,220 股 Beam Therape (納斯達克股票代碼：BEAM) 加入了Ark的投資組合，強調了其對創新型生物技術公司的關注。
Photo courtesy Benzinga YouTube and Unsplash
照片由 Benzinga YouTube 和 Uns
Read Next: Is Cathie Wood The Next Warren Buffett?
繼續閱讀：凱茜·伍德是下一個沃倫·巴菲特嗎？
Engineered by Benzinga Neuro, Edited by Shivdeep Dhaliwal
由... 設計 本辛加神經，編輯者 Shivdeep Dhaliwal
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
基於 GPT-4 的 Benzinga Neuro 內容生成系統利用廣泛的 Benzinga 生態系統，包括原生數據、API 等，爲你創建全面而及時的故事。了解更多。
譯文內容由第三人軟體翻譯。